Floatz logo

Carboplatin

Phase 2

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Phase 2 cohort.

Asset / SponsorPhaseRating
Epirubicin
M.D. Anderson Cancer Center
Phase 2CCC
Benadryl
M.D. Anderson Cancer Center
Phase 2CCC
Mezigdomide
M.D. Anderson Cancer Center
Phase 2CCC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2CCC
Elranatamab
M.D. Anderson Cancer Center
Phase 2CCC
Pembrolizumab
M.D. Anderson Cancer Center
Phase 2CCC
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →